Nathan C. Denham

Nathan C. Denham

Auto-generated profile, based on publicly available information

Nathan C. Denham

The Hull Family Cardiac Fibrillation Management Laboratory, Toronto General Hospital, University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
NDNathan C. Denham
Nathan C. Denham
CPCharles M. Pearman
Charles M. Pearman
JCJessica L. Caldwell
Jessica L. Caldwell
GMGeorge W. P. Madders
George W. P. Madders
DEDavid A. Eisner
David A. Eisner
KDKatharine M. Dibb
Katharine M. Dibb
Atrial fibrillation (AF) is commonly associated with heart failure. A bidirectional relationship exists between the two—AF exacerbates heart failure causing a significant increase in heart failure symptoms, admissions to hospital and cardiovascular death, while pathological remodeling of the atria as a result of heart failure increases the risk of AF. A comprehensive understanding of the pathophysiology of AF is essential if we are to break this vicious circle. In this review, the latest evidence will be presented showing a fundamental role for calcium in both the induction and maintenance of AF. After outlining atrial electrophysiology and calcium handling, the role of calcium-dependent afterdepolarizations and atrial repolarization alternans in triggering AF will be considered. The atrial response to rapid stimulation will be discussed, including the short-term protection from calcium overload in the form of calcium signaling silencing and the eventual progression to diastolic calcium leak causing afterdepolarizations and the development of an electrical substrate that perpetuates AF. The role of calcium in the bidirectional relationship between heart failure and AF will then be covered. The effects of heart failure on atrial calcium handling that promote AF will be reviewed, including effects on both atrial myocytes and the pulmonary veins, before the aspects of AF which exacerbate heart failure are discussed. Finally, the limitations of human and animal studies will be explored allowing contextualization of what are sometimes discordant results.

15 July 2010 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
DBDelphine Boche
Delphine Boche
NDNathan Denham
Nathan Denham
CHClive Holmes
Clive Holmes
JNJames A. R. Nicoll
James A. R. Nicoll

11 September 2018 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
NDNathan C. Denham
Nathan C. Denham
CPCharles M. Pearman
Charles M. Pearman
WDWern Yew Ding
Wern Yew Ding
JWJohan Waktare
Johan Waktare
DGDhiraj Gupta
Dhiraj Gupta
SMSaagar Mahida
Saagar Mahida

18 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
YZYanan Zhao
Yanan Zhao
BDBeibei Du
Beibei Du
PCPraloy Chakraborty
Praloy Chakraborty
NDNathan Denham
Nathan Denham
SMStéphane Massé
Stéphane Massé
KNKumaraswamy Nanthakumar
Kumaraswamy Nanthakumar
Background: We recently demonstrated that acute administration of ibrutinib, a Bruton's tyrosine kinase inhibitor used in chemotherapy for blood malignancies, increases ventricular arrhythmia (VA) vulnerability. A pathway of ibrutinib‐induced vulnerability to VA that can be modulated for cardioprotection remains unclear. Methods and Results: The effects of ibrutinib on cardiac electrical activity and Ca 2+ dynamics were investigated in Langendorff‐perfused hearts using optical mapping. We also conducted Western blotting analysis to evaluate the impact of ibrutinib on various regulatory and Ca 2+ ‐handling proteins in rat cardiac tissues. Treatment with ibrutinib (10 mg/kg per day) for 4 weeks was associated with an increased VA inducibility (72.2%±6.3% versus 38.9±7.0% in controls, P <0.002) and shorter action potential durations during pacing at various frequencies ( P <0.05). Ibrutinib also decreased heart rate thresholds for beat–to–beat duration alternans of the cardiac action potential ( P <0.05). Significant changes in myocardial Ca 2+ transients included lower amplitude alternans ratios ( P <0.05), longer times‐to‐peak ( P <0.05), and greater spontaneous intracellular Ca 2+ elevations ( P <0.01). We also found lower abundance and phosphorylation of myocardial AMPK (5′‐adenosine monophosphate‐activated protein kinase), indicating reduced AMPK activity in hearts after ibrutinib treatment. An acute treatment with the AMPK activator 5‐aminoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranoside ameliorated abnormalities in action potential and Ca 2+ dynamics, and significantly reduced VA inducibility (37.1%±13.4% versus 72.2%±6.3% in the absence of 5‐aminoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranoside, P <0.05) in hearts from ibrutinib‐treated rats. Conclusions: VA vulnerability inflicted by ibrutinib may be mediated in part by an impairment of myocardial AMPK activity. Pharmacological activation of AMPK may be a protective strategy against ibrutinib‐induced cardiotoxicity.

27 September 2024 in Heart Rhythm
Verified
Journal Article
Closed access
NDNathan Denham
Nathan Denham
SMStéphane Massé
Stéphane Massé
JAJohn Asta
John Asta
PLPatrick Lai
Patrick Lai
SBShubhayu Basu
Shubhayu Basu
KNKumaraswamy Nanthakumar
Kumaraswamy Nanthakumar

2 January 2024 in Heart Rhythm
Verified
Journal Article
Closed access
NDNathan Denham
Nathan Denham
WDWern Yew Ding
Wern Yew Ding
TCTimothy Campbell
Timothy Campbell
SMSimon Modi
Simon Modi
VLVishal Luther
Vishal Luther
SMSaagar Mahida
Saagar Mahida